Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir
The Pharma Data
MARCH 8, 2021
Since licensed by Ridgeback all funds used for the development of EIDD-2801 by Ridgeback have been provided by Wayne and Wendy Holman and Merck. About Molnupiravir. EIDD-2801 was invented at Drug Innovations at Emory (DRIVE), LLC, a not-for-profit biotechnology company wholly owned by Emory University. About Ridgeback Biotherapeutics.
Let's personalize your content